entertainment -WSS

entertainment

author：hotspot 2025-09-02 22:08:12 - browse：55741

STAT's Casey Ross (left) and Kimberly Powell, NVIDIA's vice president for healthcare at the STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — In the world of drug discovery, AI progress is often measured by a single-mile marker: When will we get an AI-designed drug?

The answer remains, ambiguously, “the future,” but at STAT’s Breakthrough Summit leaders from NVIDIA and Google insisted that the impact of AI is visible today.

Kimberly Powell, vice president of healthcare for NVIDIA, pointed to an increase in investigational new drug applications filed with the Food and Drug Administration that cite AI, as well as an uptick in early-stage readouts from clinical trials, as evidence of progress. Some of the recent readouts, Powell said, show that what’s going into Phase 1 clinical trials is more successful.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Alabama frozen embryo ruling has major implications for IVF clinics

WSS

R1 RCM gets $5.8 billion buyout offer from private equity firm

6 phony surgeries that take placebo to the extreme

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Longer MASH drug regimen improved liver, Akero study finds

First over

First over

explore

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

First over

Apple is now the first public company to be valued at $3 trillion

Immune cells and nerve overgrowth may explain recurring UTI pain

Bright Health sells Medicare Advantage business to Molina

Obesity drugs seen as possible treatment for liver disease MASH

In Memoriam: Notable people who died in 2023

A solution to the after

DIEP, the 'gold standard' of breast reconstruction, is under threat

Alabama IVF ruling threatens families facing fatal genetic disease

hotspot

The public health thinking behind the CDC’s new Covid guidance

PBM reform efforts get punted in Congress

Alabama hospital puts IVF treatments on hold

A new approach to psychiatric drug development

In utero gene editing: an explainer

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

hotspot

hotspot

leisure time

hotspot